Biotech M&A Surges: AI, Oncology & Rare Diseases Drive Pharma Deals at JPM
Biopharma heads into the J.P. Morgan Healthca...
Recent headline deals by J&J, Eli Lilly, and ...
Expected 2025–2026 deal momentum is driven by...
Risks include smaller deal sizes, persistent ...
Recent headline deals by J&J, Eli Lilly, and ...
Expected 2025–2026 deal momentum is driven by...
Risks include smaller deal sizes, persistent ...










